Has Willibaldo Ojeda, MD received payments from drug or device companies?

Yes. Drug and device makers reported $15,063 in general payments to Willibaldo Ojeda, MD across 311 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Willibaldo Ojeda, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Willibaldo Ojeda, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Willibaldo Ojeda, MD

Clinical Cardiac Electrophysiology · Bayamon, PRNPI 1689879009

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $9,600 of the $15,063 with a category attached, or 63.7%. Abbott accounts for 61.6% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $4,980 and has fallen 75.6% since, to $1,214 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in PR, where the typical reported total is $31,516.

$15,063in general payments, 2019–2025

Across 311 payments — averaging $48.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$9K
Medtronic$5K
Johnson & Johnson$188
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$187
Cook Medical LLC$134
E.r. Squibb & Sons, L.L.C.$104
plus $183 from 8 others

$59,480in research payments, 2019–2025

Across 19 payments — averaging $3130.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Abbott$59K

What the payments were for

Travel & lodging$9,60064%
Food & beverage$5,46336%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	165	$9,281
Medtronic(2 entities)	91	$4,985
Johnson & Johnson	11	$188
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	12	$187
Cook Medical LLC	15	$134
E.r. Squibb & Sons, L.L.C.	7	$104
Abiomed	2	$41
Pfizer	2	$33
Vital Connect, Inc	1	$26
Cardiovascular Systems Inc.	1	$22
Cordis US CORP.	1	$16
Novartis	1	$15
Terumo Medical Corporation	1	$15
Actelion Pharmaceuticals US, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AVEIR$3,394
Micra$2,395
AMPLATZER AMULET$1,341
EnSite Precision Cardiac Mapping System$1,095

How this compares

$15,063 in reported general payments places this provider in the 30th percentile of 22 clinical cardiac electrophysiology providers in Puerto Rico.

See all clinical cardiac electrophysiology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$341,991

Medicare patients

486

Services billed

1,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	115	$83,460
XareltoRivaroxaban	35	$31,178
Flecainide Acetate	67	$1,940
Metoprolol Succinate	56	$782
Amiodarone Hcl	40	$758
Digoxin	21	$373
Cephalexin	147	$253
SotalolSotalol Hcl	15	$215
Clindamycin Hcl	26	$76
Metoprolol Tartrate	18	$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$33	$83,460115 claims
Johnson & JohnsonXarelto	$188	$31,17835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 22 clinical cardiac electrophysiology providers in Puerto Rico.

Other clinical cardiac electrophysiology in Bayamon

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →